TY - JOUR
T1 - Current perspectives on therapeutic antibodies
AU - Yoon, Soomin
AU - Kim, Yong Sung
AU - Shim, Hyunbo
AU - Chung, Junho
PY - 2010/10
Y1 - 2010/10
N2 - Since the first monoclonal antibody, muromonab-CD3, was approved for therapeutic use in 1986, numerous molecules have been targeted using therapeutic antibody technology, resulting in 26 therapeutic antibodies being approved by the US FDA as of November, 2009. Initial concerns regarding antibody drugs focused on immunogenicity, short serum half-life, and weak efficacy. As the types of antibodies progressed from murine to chimeric, humanized, and fully human antibodies, great progress has been made in immunogenicity and in vivo instability issues. For example, humanized antibodies, such as bevacizumab, exhibit less than 0.2% immunogenicity and a 20 day serum half-life, which is comparable to native immunoglobulin. Some recently developed antibodies are exceedingly efficacious and have become first-line therapy for their target diseases. Here, we address and analyze all clinically approved therapeutic antibodies to date by discussing immunogenicity, half-life, and efficacy.
AB - Since the first monoclonal antibody, muromonab-CD3, was approved for therapeutic use in 1986, numerous molecules have been targeted using therapeutic antibody technology, resulting in 26 therapeutic antibodies being approved by the US FDA as of November, 2009. Initial concerns regarding antibody drugs focused on immunogenicity, short serum half-life, and weak efficacy. As the types of antibodies progressed from murine to chimeric, humanized, and fully human antibodies, great progress has been made in immunogenicity and in vivo instability issues. For example, humanized antibodies, such as bevacizumab, exhibit less than 0.2% immunogenicity and a 20 day serum half-life, which is comparable to native immunoglobulin. Some recently developed antibodies are exceedingly efficacious and have become first-line therapy for their target diseases. Here, we address and analyze all clinically approved therapeutic antibodies to date by discussing immunogenicity, half-life, and efficacy.
KW - efficacy
KW - immunogenicity
KW - serum half-life
KW - therapeutic monoclonal antibody
UR - http://www.scopus.com/inward/record.url?scp=78649708348&partnerID=8YFLogxK
U2 - 10.1007/s12257-009-3113-1
DO - 10.1007/s12257-009-3113-1
M3 - Review article
AN - SCOPUS:78649708348
SN - 1226-8372
VL - 15
SP - 709
EP - 715
JO - Biotechnology and Bioprocess Engineering
JF - Biotechnology and Bioprocess Engineering
IS - 5
ER -